Lifecore Biomedical will provide its earnings results for the second quarter and 6 months ended June 30, 2026, and a corporate update. The company reaffirmed its full-year 2026 guidance for revenue of $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million. Second-quarter revenue was $34.2 million, down 6.2% from $36.4 million a year earlier, while the net loss widened to $6.2 million from $1.1 million. Lifecore added six new programs in the quarter and expects contractually committed fill/finish demand from its largest customer to double beginning in 2027.
Lifecore Biomedical Inc.Reaffirmed guidance and added six new programs, with contractually committed fill/finish demand from largest customer expected to double in 2027.
